Overview

Bioimaging Study of 89Zr-M7824 in NSCLC

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a bioimaging study of 89Zr-M7824 PET scans in patients with advanced or metastatic non-small cell lung cancer who will be receiving M7824 alone or with standard of care chemotherapy. M7824 is a bifunctional fusion protein that combines an anti-PD-L1 antibody and the extracellular domain of TGFβ receptor II (TGFβRII) as a TGFβ neutralizing 'trap', into a single molecule.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Olivia Newton-John Cancer Research Institute
Collaborators:
Austin Health
Merck Healthcare KGaA